SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY

November 25, 2020

SBI Pharmaceuticals Co., Ltd.

TAGCyx biotechnologies Inc.

SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY

SBI Pharmaceuticals Co., Ltd., Tokyo, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research and develop collaboration to develop innovative products in the field of cancer treatment.

SBI Pharmaceuticals is specialized in the application of 5-ALA (5-aminolevulinic acid) and is dedicated to provide innovation for a wide range of health applications in the healthcare and health food field in order to help improve the health and quality of human life all over the world.

TAGCyx has invented artificial nucleic acid base-pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”.

By combining SBI Pharmaceuticals’ technology and TAGCyx’s Xenoligo®, both companies intend to develop novel technologies in oncology arena.

As part of the joint research and development, TAGCyx will receive research and development funds, multiple milestones at certain steps during the development as well as sales related royalties accordingly.

(*1) 5-aminolevulinic acid (5-ALA):  An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.:

Tel: 03-6229-0095  E-Mail:  info_ala@sbigroup.co.jp

TAGCyx biotechnologies Inc.

E-Mail:  info@tagcyx.com